dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
Published 4 years ago • 243 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
1:22
dr. burke on the ongoing first-mind trial with tafasitamab in dlbcl
-
6:05
l-mind study: r/r dlbcl
-
6:37
l-mind trial in relapsed/refractory dlbcl
-
1:36
the use of tafasitamab and lenalidomide in r/r dlbcl
-
1:28
first-mind: phase ib study of r-chop tafasitamab ± lenalidomide in newly diagnosed dlcbl
-
2:02
dr. kahl on promising research in chronic lymphocytic leukemia
-
0:54
dr. burke on research with tafasitamab in lymphoma
-
1:25
dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
-
2:05
dr. kahl on the impact of venetoclax in chronic lymphocytic leukemia
-
1:09
dr. flinn on opportunities for second-line tafasitamab in dlbcl
-
1:17
dr. kahl on treatment strategies for indolent lymphoma
-
1:41
real-world efficacy of tafasitamab lenalidomide in r/r dlbcl & the importance of patient selection
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
1:35
long-term follow-up of tafasitamab and lenalidomide in r/r dlbcl
-
1:49
dr. kahl discusses the construction of adcs for lymphoma treatment
-
5:50
what is the most promising novel agent for the treatment of aggressive b-cell lymphoma?
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl